Pneumocystis pneumonia in children receiving chemotherapy

Pediatr Blood Cancer. 2008 Apr;50(4):896-8. doi: 10.1002/pbc.21202.

Abstract

Pneumocystis pneumonia (PCP) is a serious complication of chemotherapy-induced immunosuppression. Trimethoprim-sulfamethoxazole (TMP-SMZ) given twice daily, 3 days every week is considered the best form of prophylaxis for PCP. We evaluated PCP prophylaxis in all children up to 18 years of age undergoing cancer chemotherapy over a 2-year period. Four children were diagnosed with PCP over 24 months. Two of 12 children on intravenous pentamidine, 1 of 143 on TMP-SMZ and 1 of 36 on dapsone for PCP prophylaxis developed PCP. Intravenous pentamidine may not be as effective as previously considered and should be used with caution.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Anti-Infective Agents / therapeutic use*
  • Antibiotic Prophylaxis
  • Antineoplastic Agents / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immunocompromised Host*
  • Infant
  • Infusions, Intravenous
  • Male
  • Neoplasms / drug therapy
  • Opportunistic Infections / complications
  • Pentamidine / administration & dosage*
  • Pneumonia, Pneumocystis / epidemiology
  • Pneumonia, Pneumocystis / immunology*
  • Pneumonia, Pneumocystis / prevention & control*
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use*

Substances

  • Anti-Infective Agents
  • Antineoplastic Agents
  • Pentamidine
  • Trimethoprim, Sulfamethoxazole Drug Combination